173 related articles for article (PubMed ID: 22239591)
1. Polyunsaturated fatty acids in emerging psychosis.
Mossaheb N; Schloegelhofer M; Schaefer MR; Fusar-Poli P; Smesny S; McGorry P; Berger G; Amminger GP
Curr Pharm Des; 2012; 18(4):576-91. PubMed ID: 22239591
[TBL] [Abstract][Full Text] [Related]
2. Polyunsaturated fatty acids in emerging psychosis: a safer alternative?
Schlögelhofer M; Amminger GP; Schaefer MR; Fusar-Poli P; Smesny S; McGorry P; Berger G; Mossaheb N
Early Interv Psychiatry; 2014 Aug; 8(3):199-208. PubMed ID: 24861004
[TBL] [Abstract][Full Text] [Related]
3. Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial.
Amminger GP; Schäfer MR; Papageorgiou K; Klier CM; Cotton SM; Harrigan SM; Mackinnon A; McGorry PD; Berger GE
Arch Gen Psychiatry; 2010 Feb; 67(2):146-54. PubMed ID: 20124114
[TBL] [Abstract][Full Text] [Related]
4. Omega-3 fatty acid supplementation changes intracellular phospholipase A2 activity and membrane fatty acid profiles in individuals at ultra-high risk for psychosis.
Smesny S; Milleit B; Hipler UC; Milleit C; Schäfer MR; Klier CM; Holub M; Holzer I; Berger GE; Otto M; Nenadic I; Berk M; McGorry PD; Sauer H; Amminger GP
Mol Psychiatry; 2014 Mar; 19(3):317-24. PubMed ID: 23478748
[TBL] [Abstract][Full Text] [Related]
5. Predictors of treatment response in young people at ultra-high risk for psychosis who received long-chain omega-3 fatty acids.
Amminger GP; Mechelli A; Rice S; Kim SW; Klier CM; McNamara RK; Berk M; McGorry PD; Schäfer MR
Transl Psychiatry; 2015 Jan; 5(1):e495. PubMed ID: 25585167
[TBL] [Abstract][Full Text] [Related]
6. [Early detection of psychotic disorders].
Schäfer MR; Klier CM; Papageorgiou K; Friedrich MH; Amminger GP
Neuropsychiatr; 2007; 21(1):37-44. PubMed ID: 17555006
[TBL] [Abstract][Full Text] [Related]
7. Effects of Omega 3 Fatty Acids on Main Dimensions of Psychopathology.
Bozzatello P; De Rosa ML; Rocca P; Bellino S
Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32839416
[TBL] [Abstract][Full Text] [Related]
8. A randomised, double-blind, placebo-controlled trial of minocycline and/or omega-3 fatty acids added to treatment as usual for at-risk mental states (NAYAB): study protocol.
Qurashi I; Chaudhry IB; Khoso AB; Farooque S; Lane S; Husain MO; Chu S; Sarginson J; Hamarani M; Naqvi HA; Razzaque B; Minhas FA; Yung AR; Deakin JFW; Husain N
Trials; 2017 Nov; 18(1):524. PubMed ID: 29121974
[TBL] [Abstract][Full Text] [Related]
9. NEURAPRO-E study protocol: a multicentre randomized controlled trial of omega-3 fatty acids and cognitive-behavioural case management for patients at ultra high risk of schizophrenia and other psychotic disorders.
Markulev C; McGorry PD; Nelson B; Yuen HP; Schaefer M; Yung AR; Thompson A; Berger G; Mossaheb N; Schlögelhofer M; Smesny S; de Haan L; Riecher-Rössler A; Nordentoft M; Chen EYH; Verma S; Hickie I; Amminger GP
Early Interv Psychiatry; 2017 Oct; 11(5):418-428. PubMed ID: 26279065
[TBL] [Abstract][Full Text] [Related]
10. Polyunsaturated fatty acids and peripheral artery disease.
Grenon SM; Hughes-Fulford M; Rapp J; Conte MS
Vasc Med; 2012 Feb; 17(1):51-63. PubMed ID: 22363018
[TBL] [Abstract][Full Text] [Related]
11. A review of the possible role of the essential fatty acids and fish oils in the aetiology, prevention or pharmacotherapy of schizophrenia.
Akter K; Gallo DA; Martin SA; Myronyuk N; Roberts RT; Stercula K; Raffa RB
J Clin Pharm Ther; 2012 Apr; 37(2):132-9. PubMed ID: 21501206
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of Polyunsaturated Fatty Acids (PUFAs) on Impulsive Behaviours and Aggressiveness in Psychiatric Disorders.
Bellino S; Bozzatello P; Badino C; Mantelli E; Rocca P
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33435512
[TBL] [Abstract][Full Text] [Related]
13. Indicated prevention with long-chain polyunsaturated omega-3 fatty acids in patients with 22q11DS genetically at high risk for psychosis. Protocol of a randomized, double-blind, placebo-controlled treatment trial.
Armando M; De Crescenzo F; Vicari S; Digilio MC; Pontillo M; Papaleo F; Amminger GP
Early Interv Psychiatry; 2016 Oct; 10(5):390-6. PubMed ID: 25345540
[TBL] [Abstract][Full Text] [Related]
14. Evidence that complement and coagulation proteins are mediating the clinical response to omega-3 fatty acids: A mass spectrometry-based investigation in subjects at clinical high-risk for psychosis.
Susai SR; Healy C; Mongan D; Heurich M; Byrne JF; Cannon M; Cagney G; Wynne K; Markulev C; Schäfer MR; Berger M; Mossaheb N; Schlögelhofer M; Smesny S; Hickie IB; Berger GE; Chen EYH; de Haan L; Nieman DH; Nordentoft M; Riecher-Rössler A; Verma S; Street R; Thompson A; Yung AR; Nelson B; McGorry PD; Föcking M; Amminger GP; Cotter D
Transl Psychiatry; 2022 Oct; 12(1):454. PubMed ID: 36307392
[TBL] [Abstract][Full Text] [Related]
15. Polyunsaturated fatty acids (PUFAs) for children with specific learning disorders.
Tan ML; Ho JJ; Teh KH
Cochrane Database Syst Rev; 2012 Dec; 12():CD009398. PubMed ID: 23235675
[TBL] [Abstract][Full Text] [Related]
16. Recent Evidence on the Role of Dietary PUFAs in Cancer Development and Prevention.
D'Archivio M; Scazzocchio B; Vari R; Santangelo C; Giovannini C; Masella R
Curr Med Chem; 2018; 25(16):1818-1836. PubMed ID: 29210633
[TBL] [Abstract][Full Text] [Related]
17. [Psychosis prevention: expectations met].
Bechdolf A; Peukert R
Psychiatr Prax; 2011 Feb; 38(2):58-60. PubMed ID: 21394689
[No Abstract] [Full Text] [Related]
18. Recommendations of the Spanish Menopause Society on the consumption of omega-3 polyunsaturated fatty acids by postmenopausal women.
Sánchez-Borrego R; von Schacky C; Osorio MJA; Llaneza P; Pinto X; Losa F; Navarro MC; Lubián D; Mendoza N
Maturitas; 2017 Sep; 103():71-77. PubMed ID: 28778336
[TBL] [Abstract][Full Text] [Related]
19. Polyunsaturated fatty acid supplementation for schizophrenia.
Joy CB; Mumby-Croft R; Joy LA
Cochrane Database Syst Rev; 2003; (2):CD001257. PubMed ID: 12804400
[TBL] [Abstract][Full Text] [Related]
20. Effect of omega-3 fatty acids for indicated prevention of young patients at risk for psychosis: when do they begin to be effective?
Mossaheb N; Schäfer MR; Schlögelhofer M; Klier CM; Cotton SM; McGorry PD; Amminger GP
Schizophr Res; 2013 Aug; 148(1-3):163-7. PubMed ID: 23778032
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
